What the Biotech Trader Screen Does—and Does Not Do

Kalshi requires employment verification for every trader participating in its biotech pilot, which covers selected late-stage clinical-trial outcomes and FDA decisions. The screen helps identify people whose work may connect them to material nonpublic information or an event’s outcome. It is not clearance to trade or proof that every eligible trader has only public information.

Answer these three eligibility questions; the result updates immediately.

That distinction matters before treating a biotech contract’s price as a clean probability. Passing an employment screen does not override Kalshi’s prohibited-trading rules, remove information risk or establish that a contract is correctly priced.

What Kalshi Has Publicly Said

Kalshi and AppliedXL launched the pilot in July 2026 with three relevant safeguards:

• It focuses on selected late-stage trials and regulatory decisions.
• A clinical-trial market is listed only after enrollment closes.
• Employment verification is required for all traders in these markets.

Kalshi’s pilot announcement calls the employment check an “additional integrity measure” and says its existing prohibition on trading with material nonpublic information still applies.

The exchange had already introduced employment screening for markets it considers unusually vulnerable to insider trading or manipulation. Its broader market-integrity announcement says it collects employment information before a trader can participate, then uses that information to identify and screen out presumptive insiders.

Public reporting provides a clue about that broader program’s workflow. Affected traders submit employment information through an online form. A Kalshi spokesperson told NBC News that employment would not routinely be verified unless an investigation warranted it, although a person could be blocked from particular contracts based on their employment.

Kalshi’s public biotech announcement does not say:

• which employer details or documents a biotech trader must provide;
• whether an outside database or vendor checks every submission;
• how contractors, consultants, clinicians, researchers or former employees are handled;
• whether a rejected trader can appeal; or
• which employer relationships trigger a block for each contract.

“Employment verification” therefore should not be read as a promise that Kalshi independently confirms every detail of every trader’s work history. The eligibility screen, Kalshi’s exchange rules and the individual contract terms control.

Disclosure Does Not Grant Permission To Trade

Employment disclosure does not replace Kalshi’s trading restrictions. Kalshi says its rules prohibit trading by:

• anyone with access—or positioned to gain access—to material nonpublic information;
• an employee or affiliate of a source agency for the contract; or
• anyone who directly or indirectly makes, or can influence, the underlying decision.

Those categories appear in Kalshi’s prohibited-trading guidance. For a biotech contract, relevant relationships could extend beyond the drug sponsor’s employees. Depending on the facts and contract terms, a clinical site, contract research organization, laboratory, regulator or another organization involved in the outcome or resolution record may matter.

Entering an employer’s name does not make an otherwise prohibited trade permissible. Someone holding material nonpublic information should not participate merely because the eligibility screen accepts an order.

Screening Cannot Remove Information Risk

AppliedXL, which provides resolution analysis for the pilot, says employment verification can identify certain direct relationships but cannot uncover every possible source of material nonpublic information. The pilot therefore combines eligibility restrictions with employment- or identity-related checks and market surveillance.

Kalshi—not AppliedXL—operates the exchange, conducts investigations and has final authority over resolution under its rules, according to AppliedXL’s pilot FAQ.

The limits are straightforward:

• Someone can receive confidential information outside employment.
• Employer records may not reveal personal or informal advisory relationships.
• A job title may not show what information the person can access.
• Screening and surveillance can deter or detect misconduct without guaranteeing its absence.

The safeguard still has value because it gives Kalshi information it can use to block apparent conflicts and investigate unusual trading. But biotech prices can also reflect liquidity, sentiment, timing and market structure—not just well-calibrated scientific forecasts.

Read The Contract Before Reading The Price

The pilot’s contracts resolve from specified public records. Depending on the question, that may include a ClinicalTrials.gov record, an FDA action document or an advisory-committee vote record. AppliedXL assesses the named evidence against criteria set before trading, while Kalshi retains final settlement authority. The launch release gives examples involving a Phase 3 primary endpoint and an FDA approval decision.

Before trading, check four things:

1. The exact proposition. “Meets the registered primary endpoint” is not the same as “the drug works,” “the company reports positive results” or “the FDA approves it.”
2. The resolution source. Identify the controlling document and any hierarchy that applies when sources conflict.
3. The deadline and exceptions. Look for rules covering delayed results, changed endpoints, corrections, ambiguity or missing documents.
4. Your eligibility. Complete the employment check truthfully and confirm that neither your relationships nor your information make you a prohibited participant.

This is an especially important market in which to use a full pre-trade reading checklist.

A 42-Cent Contract Still Needs Price Analysis

Suppose a biotech Yes contract displays a best Yes ask of 42¢, a best Yes bid of 39¢, a 3¢ spread and a settlement value of $1 if Yes, $0 if No.

Buying one Yes contract at 42¢ puts 42¢ at risk before fees. If Yes settles, the gross gain is $1.00 − $0.42 = $0.58. If No settles, the 42¢ purchase price is lost.

If the displayed bid remains available and an immediate sell order fills at 39¢, the round trip loses 3¢ before fees: $0.42 − $0.39 = $0.03.

For a transparent illustration, assume a flat 2¢ total fee per contract, paid regardless of the result. If p is your probability of Yes, the hold-to-settlement break-even calculation is p × $1.00 − $0.42 − $0.02 = $0, so p = 0.44, or 44%.

This is only a simplifying assumption. Actual fees depend on the order and applicable fee schedule, so use the fee in Kalshi’s order preview for a real trade.

Employment verification may reduce one integrity risk. It does not show that 42¢ is a good price, guarantee a liquid exit or turn a market price into clinical evidence. AppliedXL expressly says patients should not use these prices for treatment or trial-participation decisions; those decisions belong with qualified medical professionals.